<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886544</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL025</org_study_id>
    <nct_id>NCT04886544</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring</brief_title>
  <official_title>A Multicenter, Randomized, Evaluator-Blinded, No-Treatment Control Design Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Evaluator-Blinded, No-Treatment Control Design Clinical Study to Evaluate the&#xD;
      Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Multicenter, Randomized, Evaluator-Blinded, No-Treatment Control Design Clinical&#xD;
      Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline&#xD;
      Contouring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary effectiveness endpoint is the Jawline Contour Rating Scale (JCRS) responder rate at 26 weeks after the last injection</measure>
    <time_frame>26 weeks from baseline</time_frame>
    <description>The primary effectiveness endpoint is the Jawline Contour Rating Scale (JCRS) responder rate at 26 weeks after the last injection for the test group and at Week 26 for the control group, i.e., the proportion of subjects with ≥1 grade improvement on the JCRS score (both jawlines) rated by independent blinded Evaluators at the site (Evaluating Investigator) at Visit 5, compared to that at Baseline (Visit 1).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Jaw Volume Deficit</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyaluronic acid dermal filler at Week 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Remain untreated until Week 26</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE Y-Solution 720</intervention_name>
    <description>Hyaluronic acid dermal filler</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults 18 - 75 years of age (inclusive)&#xD;
&#xD;
          -  2 (moderate) or 3 (severe) on Jawline Contour Rating Scale (JCRS)&#xD;
&#xD;
          -  want a filler injection procedure for the replacement of volume loss in the jawlines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have an active or infective skin disease&#xD;
&#xD;
          -  have lower-face volume deficit due to congenital defect, trauma, abnormalities in&#xD;
             adipose tissue related to immune-mediated diseases&#xD;
&#xD;
          -  have a tattoo or excessive facial hair in the evaluation area&#xD;
&#xD;
          -  have received permanent facial implants&#xD;
&#xD;
          -  have undergone semi-permanent filler within 24 months&#xD;
&#xD;
          -  have undergone temporary dermal filler treatment in the lower face (below the orbital&#xD;
             rim) within 12 months&#xD;
&#xD;
          -  have streptococcal disease&#xD;
&#xD;
          -  have a medical history of hypertrophic cicatrix, hyperpigmentation or keloid&#xD;
&#xD;
          -  have a history of anaphylaxis, multiple severe allergies, or allergy to lidocaine (or&#xD;
             any amide-based anesthetic), or hyaluronic acid products&#xD;
&#xD;
          -  have history of bleeding disorder&#xD;
&#xD;
          -  have severe cardiovascular, hepatic or renal diseases considered as per Investigator's&#xD;
             discretion&#xD;
&#xD;
          -  have known malignant tumors or cancerous or precancerous lesion&#xD;
&#xD;
          -  positive pregnancy test indicating pregnancy&#xD;
&#xD;
          -  active COVID-19 infection and suspected COVID-19 infection within the past 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>LG Chem Investigational site 01</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LG Chem investigational site 01</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LG Chem investigational site 02</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

